HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US COVID-19 Relief Package Boosts Pharma Manufacturing Programs – More To Come?

Executive Summary

$10bn here and $6bn there on top of what’s left from earlier CARES Act gives government more options on COVID-19 medical countermeasures.

You may also be interested in...



FDA Left Out Of $80M For Stopping Consumer Product Fraud In Latest US COVID-19 Relief Act

American Rescue Plan Act appropriated $50m to Consumer Product Safety Commission and $30.4m to Federal Trade Commission for COVID-19-related enforcement. Neither agency received funding for pandemic-related enforcement in previous relief packages.

US FDA Would See Cash Windfall In COVID-19 Relief Bill

The $500m in additional funds would support pandemic-related activities, potentially for additional staff or technology upgrades.

Initial List Of US Essential Medicines Focuses On Acute Care

US FDA excludes chronic care products from list of medicines bolstered by domestic production investment and federal procurement requirements.

Related Content

Topics

UsernamePublicRestriction

Register

RS151127

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel